BBS-Bioactive Bone Substitutes Oyj
BBS-Bioactive Bone Substitutes Oyj, a biomedical technology company, develops, manufactures, and commercializes bioactive medical devices and implants for orthopedic surgery in Finland. It offers ARTEBONE, an orthobiological product based on tricalcium phosphate and natural spectrum of bone proteins used primarily for the treatment of bone defects and healing problems in extremities, such as foot… Read more
BBS-Bioactive Bone Substitutes Oyj (BONEH) - Total Liabilities
Latest total liabilities as of June 2024: €5.58 Million EUR
Based on the latest financial reports, BBS-Bioactive Bone Substitutes Oyj (BONEH) has total liabilities worth €5.58 Million EUR as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BBS-Bioactive Bone Substitutes Oyj - Total Liabilities Trend (2014–2023)
This chart illustrates how BBS-Bioactive Bone Substitutes Oyj's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BBS-Bioactive Bone Substitutes Oyj Competitors by Total Liabilities
The table below lists competitors of BBS-Bioactive Bone Substitutes Oyj ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stayble Therapeutics AB
ST:STABL
|
Sweden | Skr1.44 Million |
|
Av Gad Holdings Ltd
TA:AVGD
|
Israel | ILA495.68 Million |
|
ZWACK UNICUM
MU:ZWC1
|
Germany | €7.52 Billion |
|
DEVRY EDUCATION GRP - Dusseldorf Stock Exchang
DU:DVY
|
Germany | €1.43 Billion |
|
Imaspro Corporation Bhd
KLSE:7222
|
Malaysia | RM6.42 Million |
|
Clean Motion AB
ST:CLEMO
|
Sweden | Skr15.79 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down BBS-Bioactive Bone Substitutes Oyj's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BBS-Bioactive Bone Substitutes Oyj's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BBS-Bioactive Bone Substitutes Oyj (2014–2023)
The table below shows the annual total liabilities of BBS-Bioactive Bone Substitutes Oyj from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €5.50 Million | -14.21% |
| 2022-12-31 | €6.42 Million | -6.63% |
| 2021-12-31 | €6.87 Million | +4.04% |
| 2020-12-31 | €6.61 Million | -2.19% |
| 2019-12-31 | €6.75 Million | +0.21% |
| 2018-12-31 | €6.74 Million | -21.63% |
| 2017-12-31 | €8.60 Million | +4.80% |
| 2016-12-31 | €8.21 Million | +2.70% |
| 2015-12-31 | €7.99 Million | +9.60% |
| 2014-12-31 | €7.29 Million | -- |